Zymeworks Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 0
Bid Price
Ask Price
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Zymeworks Inc ZYME NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 6.73 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 4.56 - 37.19
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 6.73 USD


Draw Mode:

Zymeworks Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 389.62M 57.89M 57.86M $ 26.67M $ - -4.37 -1.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 203.05k 0.80%

more financials information »

Zymeworks News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ZYME Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.,372,1040.477.51%
1 Month5.507.295.356.23872,4121.2322.36%
3 Months5.757.604.9556.141,145,7470.9817.04%
6 Months7.858.184.566.281,411,174-1.12-14.27%
1 Year33.7337.194.5610.861,091,953-27.00-80.05%
3 Years24.6259.034.5622.64646,596-17.89-72.66%
5 Years7.175659.034.5622.08434,956-0.4456-6.21%

Zymeworks Description

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now